<p>马萨诸塞州剑桥和丹麦哥本哈根，2026 年 4 月 30 日（环球新闻通讯社）—— Hemab Therapeutics Holdings, Inc.（纳斯达克：COAG），一家临床阶段的生物技术公司，正在开发重新构想血液凝固障碍治疗的疗法，以维持生命和人类的韧性，今天宣布其首次公开募股的定价，发行 16,750,000 股普通股，公开发行价格为每股 18.00 美元。此外，Hemab 已向承销商授予 30 天的选择权，以公开发行价格购买最多 2,512,500 股普通股，扣除承销折扣和佣金。所有普通股均由 Hemab 提供。</p>
<p>Hemab 的普通股预计将于 2026 年 5 月 1 日星期五在纳斯达克全球精选市场开始交易，股票代码为 “COAG”。在扣除 Hemab 应支付的承销折扣和佣金及其他发行费用之前，预计此次发行的总收益约为 3.015 亿美元，不包括承销商选择权的任何行使。此次发行预计将在 2026 年 5 月 4 日左右完成，具体情况取决于惯例的交割条件。</p>
<p>高盛公司、杰弗里金融和 Evercore ISI 担任此次发行的联合账簿管理人。Wedbush PacGrow 担任此次发行的首席管理人。</p>
<p>与此次发行相关的证券注册声明已向证券交易委员会提交，并于 2026 年 4 月 30 日获得有效。此次发行仅通过招股说明书进行。最终招股说明书的副本在可用时可从高盛公司索取，注意：招股说明书部门，地址：200 West Street, New York, NY 10282，电话：1-866-471-2526，或通过电子邮件联系：prospectus-ny@ny.email.gs.com；杰弗里金融，注意：股权承销招股说明书部门，地址：520 Madison Avenue, New York, NY 10022，电话：(877) 821-7388，或通过电子邮件联系：Prospectus_Department@Jefferies.com；或 Evercore Group L.L.C.，注意：股权资本市场，地址：55 East 52nd Street, New York, NY 10055，电话：(888) 474-0200，或通过电子邮件联系：ecm.prospectus@evercore.com。</p>
<p>本新闻稿不构成出售这些证券的要约，也不构成购买这些证券的要约邀请，亦不应在任何州或司法管辖区内进行这些证券的要约、邀请或销售，若在任何此类州或司法管辖区内的证券法下未进行注册或资格审查，则此类要约、邀请或销售将是非法的。</p>
<p><strong>关于 Hemab Therapeutics</strong></p>
<p>Hemab Therapeutics Holdings, Inc.是一家临床阶段的生物技术公司，正在开发重新构想血液凝固障碍治疗的疗法，以维持生命和人类的韧性。Hemab 的使命是为全球数百万患有严重出血和血栓性疾病的患者发现、开发和商业化创新疗法。Hemab 正在建立一系列创新疗法，旨在解决凝固障碍治疗中的关键空白，包括 sutacimig（HMB-001），一种正在临床开发中的双特异性抗体，用于 Glanzmann 血小板无力症和 VII 因子缺乏症的预防性治疗，以及 HMB-002，一种正在临床开发中的单价抗体，用于 Von Willebrand 病的预防性治疗。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿中关于未来期望、计划和前景的声明，以及关于非历史事实的其他声明，可能构成 “前瞻性声明”。这些声明包括但不限于与首次公开募股的交割日期、在纳斯达克全球精选市场的交易开始以及预计的发行总收益相关的声明。词语 “预期”、“相信”、“继续”、“可能”、“估计”、“期望”、“打算”、“可能”、“计划”、“潜在”、“预测”、“项目”、“应该”、“目标”、“将”、“会” 等类似表达旨在识别前瞻性声明，尽管并非所有前瞻性声明都包含这些或类似的识别词。实际结果可能因各种重要因素而与这些前瞻性声明所指示的结果有重大差异，包括：与市场条件相关的不确定性以及首次公开募股是否按预期条款完成的其他因素，以及在向证券交易委员会提交的有效注册声明的初步招股说明书的 “风险因素” 部分中讨论的其他因素。本新闻稿中包含的任何前瞻性声明均基于 Hemab 管理团队当前的期望，仅在本日期有效，Hemab 特别声明不承担更新任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因，法律要求的除外。</p>
<p><strong>媒体：</strong></p>
<p>德尔菲德</p>
<p>佩格·鲁斯科尼</p>
<p>peg.rusconi@deerfieldgroup.com</p>
<p><strong>投资者：</strong></p>
<p>Hemab Therapeutics</p>
<p>马兹·贝恩德特</p>
<p>investors@hemab.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE1URTNNU00zTlRjM05qYzNJekl6TVRBeU56RT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE1URTNNU00zTlRjM05qYzNJekl6TVRBeU56RT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODA2NTAwNWItYjg4Mi00M2QxLTk5MGMtYWQwYjJlMGZiNzYzLTEzMjE4MjEtMjAyNi0wNC0zMC1lbg==/tiny/Hemab-Therapeutics-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODA2NTAwNWItYjg4Mi00M2QxLTk5MGMtYWQwYjJlMGZiNzYzLTEzMjE4MjEtMjAyNi0wNC0zMC1lbg==/tiny/Hemab-Therapeutics-Inc-.png"/></p>

高盛

<p>Hemab Therapeutics Holdings, Inc. 将其首次公开募股（IPO）定价为每股 18.00 美元，提供 16,750,000 股，并给予承销商购买额外 2,512,500 股的选择权。此次 IPO 预计将筹集约 3.015 亿美元，并将于 2026 年 5 月 1 日在纳斯达克以 “COAG” 为股票代码开始交易。此次发行预计将在 2026 年 5 月 4 日左右结束，具体情况需遵循惯例条件。高盛、杰富瑞和 Evercore ISI 是此次发行的联合账簿管理人</p>

<p>CAMBRIDGE, Mass. and COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced the pricing of its initial public offering of 16,750,000 shares of its common stock at a public offering price of $18.00 per share. In addition, Hemab has granted the underwriters a 30-day option to purchase up to an additional 2,512,500 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by Hemab.</p>
<div class="lb-trans"><p>马萨诸塞州剑桥和丹麦哥本哈根，2026 年 4 月 30 日（环球新闻通讯社）—— Hemab Therapeutics Holdings, Inc.（纳斯达克：COAG），一家临床阶段的生物技术公司，正在开发重新构想血液凝固障碍治疗的疗法，以维持生命和人类的韧性，今天宣布其首次公开募股的定价，发行 16,750,000 股普通股，公开发行价格为每股 18.00 美元。此外，Hemab 已向承销商授予 30 天的选择权，以公开发行价格购买最多 2,512,500 股普通股，扣除承销折扣和佣金。所有普通股均由 Hemab 提供。</p>
</div><p>Hemab’s common stock is expected to begin trading on the Nasdaq Global Select Market on Friday, May 1, 2026 under the ticker symbol “COAG.” The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Hemab, are expected to be approximately $301.5 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about May 4, 2026, subject to customary closing conditions.</p>
<div class="lb-trans"><p>Hemab 的普通股预计将于 2026 年 5 月 1 日星期五在纳斯达克全球精选市场开始交易，股票代码为 “COAG”。在扣除 Hemab 应支付的承销折扣和佣金及其他发行费用之前，预计此次发行的总收益约为 3.015 亿美元，不包括承销商选择权的任何行使。此次发行预计将在 2026 年 5 月 4 日左右完成，具体情况取决于惯例的交割条件。</p>
</div><p>Goldman Sachs &amp; Co. LLC, Jefferies and Evercore ISI are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.</p>
<div class="lb-trans"><p>高盛公司、杰弗里金融和 Evercore ISI 担任此次发行的联合账簿管理人。Wedbush PacGrow 担任此次发行的首席管理人。</p>
</div><p>A registration statement relating to the securities being sold in the offering has been filed with the Securities and Exchange Commission and was declared effective on April 30, 2026. The offering is being made only by means of a prospectus. A copy of the final prospectus, when available, may be obtained from Goldman Sachs &amp; Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526, or by email at prospectus-ny@ny.email.gs.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.</p>
<div class="lb-trans"><p>与此次发行相关的证券注册声明已向证券交易委员会提交，并于 2026 年 4 月 30 日获得有效。此次发行仅通过招股说明书进行。最终招股说明书的副本在可用时可从高盛公司索取，注意：招股说明书部门，地址：200 West Street, New York, NY 10282，电话：1-866-471-2526，或通过电子邮件联系：prospectus-ny@ny.email.gs.com；杰弗里金融，注意：股权承销招股说明书部门，地址：520 Madison Avenue, New York, NY 10022，电话：(877) 821-7388，或通过电子邮件联系：Prospectus_Department@Jefferies.com；或 Evercore Group L.L.C.，注意：股权资本市场，地址：55 East 52nd Street, New York, NY 10055，电话：(888) 474-0200，或通过电子邮件联系：ecm.prospectus@evercore.com。</p>
</div><p>This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售这些证券的要约，也不构成购买这些证券的要约邀请，亦不应在任何州或司法管辖区内进行这些证券的要约、邀请或销售，若在任何此类州或司法管辖区内的证券法下未进行注册或资格审查，则此类要约、邀请或销售将是非法的。</p>
</div><p><strong>About Hemab Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 Hemab Therapeutics</strong></p>
</div><p>Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab’s mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, and HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease.</p>
<div class="lb-trans"><p>Hemab Therapeutics Holdings, Inc.是一家临床阶段的生物技术公司，正在开发重新构想血液凝固障碍治疗的疗法，以维持生命和人类的韧性。Hemab 的使命是为全球数百万患有严重出血和血栓性疾病的患者发现、开发和商业化创新疗法。Hemab 正在建立一系列创新疗法，旨在解决凝固障碍治疗中的关键空白，包括 sutacimig（HMB-001），一种正在临床开发中的双特异性抗体，用于 Glanzmann 血小板无力症和 VII 因子缺乏症的预防性治疗，以及 HMB-002，一种正在临床开发中的单价抗体，用于 Von Willebrand 病的预防性治疗。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements relating to the closing date of the initial public offering, the commencement of trading on the Nasdaq Global Select Market and the anticipated gross proceeds from the offering. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the initial public offering on the anticipated terms of the offering or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus that forms a part of the effective registration statement filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Hemab’s management team and speak only as of the date hereof, and Hemab specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.</p>
<div class="lb-trans"><p>本新闻稿中关于未来期望、计划和前景的声明，以及关于非历史事实的其他声明，可能构成 “前瞻性声明”。这些声明包括但不限于与首次公开募股的交割日期、在纳斯达克全球精选市场的交易开始以及预计的发行总收益相关的声明。词语 “预期”、“相信”、“继续”、“可能”、“估计”、“期望”、“打算”、“可能”、“计划”、“潜在”、“预测”、“项目”、“应该”、“目标”、“将”、“会” 等类似表达旨在识别前瞻性声明，尽管并非所有前瞻性声明都包含这些或类似的识别词。实际结果可能因各种重要因素而与这些前瞻性声明所指示的结果有重大差异，包括：与市场条件相关的不确定性以及首次公开募股是否按预期条款完成的其他因素，以及在向证券交易委员会提交的有效注册声明的初步招股说明书的 “风险因素” 部分中讨论的其他因素。本新闻稿中包含的任何前瞻性声明均基于 Hemab 管理团队当前的期望，仅在本日期有效，Hemab 特别声明不承担更新任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因，法律要求的除外。</p>
</div><p><strong>Media:</strong></p>
<div class="lb-trans"><p><strong>媒体：</strong></p>
</div><p>Deerfield</p>
<div class="lb-trans"><p>德尔菲德</p>
</div><p>Peg Rusconi</p>
<div class="lb-trans"><p>佩格·鲁斯科尼</p>
</div><p>peg.rusconi@deerfieldgroup.com</p>
<div class="lb-trans"><p>peg.rusconi@deerfieldgroup.com</p>
</div><p><strong>Investors:</strong></p>
<div class="lb-trans"><p><strong>投资者：</strong></p>
</div><p>Hemab Therapeutics</p>
<div class="lb-trans"><p>Hemab Therapeutics</p>
</div><p>Mads Behrndt</p>
<div class="lb-trans"><p>马兹·贝恩德特</p>
</div><p>investors@hemab.com</p>
<div class="lb-trans"><p>investors@hemab.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE1URTNNU00zTlRjM05qYzNJekl6TVRBeU56RT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTcxMTE3MSM3NTc3Njc3IzIzMTAyNzE="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODA2NTAwNWItYjg4Mi00M2QxLTk5MGMtYWQwYjJlMGZiNzYzLTEzMjE4MjEtMjAyNi0wNC0zMC1lbg==/tiny/Hemab-Therapeutics-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/ODA2NTAwNWItYjg4Mi00M2QxLTk5MGMtYWQwYjJlMGZiNzYzLTEzMjE4MjEtMjAyNi0wNC0zMC1lbg==/tiny/Hemab-Therapeutics-Inc-.png"/></p>

Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering | COAG Stock News

StockTitan

Hemab Therapeutics 宣布扩大规模的首次公开募股定价 | COAG 股票新闻